Ocugen(OCGN) - 2024 Q3 - Quarterly Results

Exhibit 99.1 Ocugen Provides Business Update with Third Quarter 2024 Financial Results Conference Call and Webcast Today at 8:30 a.m. ET • Subsequent to quarter-end, closed $30 million in debt financing • OCU400 Phase 3 liMeliGhT clinical trial for retinitis pigmentosa (RP) on track to complete enrollment in 1H2025 • OCU410 is currently in Phase 2 of the Phase 1/2 ArMaDa clinical trial • Data and Safety Monitoring Board (DSMB) for the OCU410ST GARDian clinical trial approved enrollment for the second phase ...